Articles Vol. 67 No. CĐ11-NCKH 01/08/2026

COST-UTILITY ANALYSIS OF FENOFIBRATE IN SLOWING PROGRESSION OF DIABETIC RETINOPATHY IN VIETNAM

Phung Lam Toi1,2, Ngo Thi Ngoc Nhi3,4, Usa Chaikledkaew3,4,5,6,7,8, Kyoo Kim9,10
1 University of Medicine and Pharmacy, Vietnam National University, Hanoi
2 Trường Đại học Y Dược, Đại học Quốc gia Hà Nội
3 Health Technology Assessment (MUHTA) Graduate Program, Mahidol University
4 Chương trình Sau đại học Đánh giá Công nghệ Y tế (MUHTA), Đại học Mahidol
5 Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University
6 Global Health Technology Assessment (GHTA) Research Center, Faculty of Pharmacy, Mahidol University - Bangkok, Thailan
7 Bộ môn Quản lý và Xã hội Dược, Khoa Dược, Đại học Mahidol
8 Trung tâm Nghiên cứu Đánh giá Công nghệ Y tế toàn cầu (GHTA), Khoa Dược, Đại học Mahidol
9 Abbott Products Operations AG - Switzerland
10 Abbott Products Operations AG - Thuỵ Sĩ.
DOI: 10.52163/yhc.v67iCD11.6071
49 Views
0 Downloads
Keywords
Diabetic retinopathy, Fenofibrate, cost effectiveness, cost utility analysis
Abstract

Objective: To analyze the cost-utility of Fenofibrate in slowing the progression of diabetic retinopathy in Vietnam.

Subjects and methods: A model-based cost-utility analysis was performed from the payer perspective and the societal perspective, over a 10-year time horizon. A Markov model with 9 health states was used with a 1-year cycle length. The parameters of cost, clinical efficacy, and quality of life were collected from published literature.

Results: Fenofibrate was associated with both higher costs and greater clinical benefits. Compared to standard of care, Fenofibrate yielded an additional 0.3 quality-adjusted life years (QALYs). The incremental costs were VND 25.7 million from the societal perspective and VND 34.7 million from the payer perspective. The resulting ICERs per QALY gained were VND 84.5 million and VND 114.1 million, respectively, both falling below the one GDP per capita threshold for Vietnam in 2025. Sensitivity analyses robust the base-case results.

Conclusion: Fenofibrate is cost-effective in slowing the progression of diabetic retinopathy in Vietnam.

References
[1]
Ciorba A.L, Saber S et al. Diabetic retinopathy in focus: Update on treatment advances, pharmaceutical approaches, and new technologies. Eur J Pharm Sci, 2025, 214: 107307. doi: 10.1016/j.ejps.2025.107307 Google Scholar
[2]
GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health, 2021, 9 (2): e144-e60. doi: 10.1016/s2214-109x(20)30489-7 Google Scholar
[3]
Nguyễn Thị Thủy Tiên, Trần Đình Tùng. Khảo sát bệnh lý võng mạc đái tháo đường trên bệnh nhân điều trị tại Bệnh viện Thống Nhất. Tạp chí Y học cộng đồng, 2024, 65 (CĐ10): 410-418. doi: 10.52163/yhc.v65iCD10.1657 Google Scholar
[4]
Pan Y, Li Y et al. Global, regional and national burden of blindness and vision loss attributable to diabetic retinopathy, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Diabetes Obes Metab, 2025, 27 (10): 5464-77. doi: 10.1111/dom.16588 Google Scholar
[5]
Bộ Y tế. Hướng dẫn chẩn đoán, điều trị và quản lý bệnh võng mạc đái tháo đường (Ban hành kèm theo Quyết định số 2558/QĐ-BYT ngày 20/9/2022). Google Scholar
[6]
Preiss D, Logue J et al. Effect of Fenofibrate on progression of diabetic retinopathy. NEJM Evid, 2024, 3 (8): EVIDoa2400179. doi: 10.1056/EVIDoa2400179 Google Scholar
[7]
Scotland G, Tsehaye M et al. Cost-effectiveness of Fenofibrate versus standard care for reducing the progression of diabetic retinopathy: an economic evaluation based on data from the LENS trial. Diabet Med, 2025, 42 (9): e70098. doi: 10.1111/dme.70098 Google Scholar
[8]
Pham Huy Tuan Kiet, Kieu Thi Tuyet Mai et al. Direct medical costs of diabetes and its complications in Vietnam: a national health insurance database study. Diabetes Res Clin Pract, 2020, 162: 108051. doi: 10.1016/j.diabres.2020.108051 Google Scholar
[9]
Srisubat A, Kittrongsiri K et al. Cost-utility analysis of deep learning and trained human graders for diabetic retinopathy screening in a nationwide program. Ophthalmol Ther, 2023, 12 (2): 1339-57. doi: 10.1007/s40123-023-00688-y Google Scholar
[10]
Trần Thị Hoài Vi, Nguyễn Quốc Đạt, Nguyễn Hoàng Lan. Chất lượng cuộc sống và các yếu tố liên quan ở bệnh nhân võng mạc đái tháo đường tại thành phố Đà Nẵng. Tạp chí Y Dược Huế, 2025, 15 (5): 95-102. doi: 10.34071/jmp.2025.5.13 Google Scholar